Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

BACKGROUND: TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monother...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Gastroenterol
Hlavní autoři: Sugiura, Kiyoaki, Seo, Yuki, Takahashi, Takayuki, Tokura, Hideyuki, Ito, Yasuhiro, Tanaka, Motomu, Kishida, Norihiro, Nishi, Yusuke, Onishi, Yoshihiko, Aoki, Hikaru
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058969/
https://ncbi.nlm.nih.gov/pubmed/33879100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-021-01771-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky